A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

ABSTRACT:

Importance

Currently, there is no established second-line systemic treatment for biliary tract cancer (BTC). Preclinical data have demonstrated that the presence of tumor-infiltrating CD8 T cells and programmed cell death 1 ligand 1-expressing tumor cells in the tumor microenvironment of BTC supports the rationale of using programmed cell death 1 protein blockade immunotherapy in BTC.

Objective

To evaluate anticancer activity of nivolumab in patients with advanced refractory BTC.

Design, setting, and participants

In this single-group, multicenter phase 2 study of nivolumab, 54 patients with histologically confirmed BTC whose disease progressed while undergoing treatment with at least 1 line but no more than 3 lines of systemic therapy were enrolled between October 5,

SUBMITTER: Kim RD 

PROVIDER: S-EPMC7193528 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature